NICE TAs

29/08/2024

TA997: Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma

07/08/2024

TA993: Burosumab for treating X-linked hypophosphataemia in adults

07/08/2024

TA991: Abaloparatide for treating osteoporosis after menopause

13/06/2024

TA982: Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over

05/06/2024

TA979: Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation

08/05/2024

TA971: Remdesivir and tixagevimab plus cilgavimab for treating COVID-19

08/05/2024

TA970: Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments

28/03/2024

TA962: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy

27/03/2024

TA959: Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis

27/03/2024

TA958: Ritlecitinib for treating severe alopecia areata in people 12 years and over

21/02/2024

TA952: Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations

13/12/2023

TA939: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer

22/11/2023

TA931: Zanubrutinib for treating chronic lymphocytic leukaemia

11/10/2023

TA918: Bimekizumab for treating axial spondyloarthritis

15/08/2023

TA912: Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease

28/04/2022

TA787: Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable

28/04/2022

TA786: Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies

11/10/2021

TA704: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies

11/10/2021

TA705: Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer

11/10/2021

TA706: Ozanimod for treating relapsing–remitting multiple sclerosis